Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma
- Author:
Juan GLINKA
1
;
Federico DIAZ
;
Augusto ALVA
;
Oscar MAZZA
;
Rodrigo SANCHEZ CLARIA
;
Victoria ARDILES
;
Eduardo DE SANTIBAÑES
;
Juan PEKOLJ
;
Martín DE SANTIBAÑES
Author Information
- Publication Type:Original Article
- Keywords: Pancreatic cancer; Radiotherapy; Chemoradiation
- MeSH: Adenocarcinoma; Cohort Studies; Diagnosis; Drug Therapy; Humans; Pancreatic Neoplasms; Postoperative Complications; Prospective Studies; Radiotherapy; Retrospective Studies; Sample Size
- From:Radiation Oncology Journal 2018;36(3):210-217
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Pancreatic cancer (PC) has not changed overall survival in recent years despite therapeutic efforts. Surgery with curative intent has shown the best long-term oncological results. However, 80%–85% of patients with these tumors are unresectable at the time of diagnosis. In those patients, first therapeutic attempts are minimally invasive or surgical procedures to alleviate symptoms. The addition of radiotherapy (RT) to standard chemotherapy, ergo chemoradiation, in patients with locally advanced pancreatic cancer (LAPC) is still controversial. The study aims to compare outcomes in patients with a double bypass surgery due to LAPC treated or not with RT. MATERIALS AND METHODS: A retrospective cohort study of patients with double bypass for LAPC were registered and divided into two groups: treated or not with postoperative RT. Baseline characteristics, postoperative complications, those related to RT and their relation to the main event (mortality) were compared. RESULTS: Seventy-four patients were included. Surgical complications between the groups did not offer significant differences. Complications related to RT were mostly mild, and 86% of patients completed the treatment. Overall survival at 1 and 2 years for patients in the exposed group was 64% and 35% vs. 50% and 28% in the non-exposed group, respectively (p = 0.11; power 72%; hazard ratio = 0.53; 95% confidence interval, 0.24–1.18). CONCLUSION: We observed a tendency for survival improvement in patients with postoperative RT. However, we’ve not had enough power to demonstrate this difference, possibly due to the small sample size. It is indispensable to develop randomized and prospective trials to guide more specific treatment lines in this patients.
